Your session is about to expire
← Back to Search
allogeneic hematopoietic stem cell transplantation for Leukemia
Study Summary
This trial is studying four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant to see how well they work in treating patients with relapsed or refractory hematologic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am still recovering from intense chemotherapy.My cancer affects my blood or lymphatic system.My leukemia is in remission or has poor risk factors.My heart, lungs, and kidneys meet the specific health criteria required.I have a history of cancer.I haven't had cancer in the last 5 years, except for skin cancer.I have two partially matched cord blood units available for my treatment.I don't have a fully matched family or unrelated bone marrow donor.I am infected with HIV-1.I have an ongoing infection that is not under control.My condition is a relapse of myelodysplastic syndromes or non-Hodgkin lymphoma with bone marrow involvement.I have chronic lymphocytic leukemia that hasn't responded to treatment and can't undergo high-dose chemotherapy due to other health issues.I have had a condition where lymphocytes are produced in excessive amounts.
- Group 1: Regimen I (FTBI, Cyclophosphamide, Fludarabine)
- Group 2: Regimen II (Busulfan, Fludarabine, Melphalan)
- Group 3: Regimen III (TBI, Cyclophosphamide, Fludarabine)
- Group 4: Regimen IV (Fludarabine, Melphalan)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is recruitment for this clinical research still in progress?
"This trial is not currently accepting applications. It was published on August 16th, 2005 and last modified on September 14th 2022. Patients searching for other trials may look into the 4114 clinical studies focusing on leukemia or the 1119 investigations centering around allogeneic hematopoietic stem cell transplantation which are both recruiting participants."
What are the standard indications for a hematopoietic stem cell transplant from an allogeneic source?
"Allogeneic hematopoietic stem cell transplantation can be used to address nephrotic syndrome, but it is also an effective treatment for a plethora of other conditions such as leukemia, ocular rosacea and various forms of lung cancer."
What is the enrollment count of this experiment?
"Unfortunately, this trial is no longer accepting applications. Initially posted on August 16th 2005 and last edited on September 14th 2022, the study has concluded its recruitment process. However, there are presently 4114 studies for leukemia and 1119 investigations into allogeneic hematopoietic stem cell transplantation that require participants."
Are there any other experiments that have been done related to allogeneic hematopoietic stem cell transplantation?
"The initial studies into allogeneic hematopoietic stem cell transplantation occured in 1997, conducted at City of Hope Comprehensive Cancer Center. As of now, there are a total 2158 completed clinical trials and 1119 active investigations underway - many hailing from Duarte, California."
Could I potentially qualify for this medicinal research program?
"The current trial is seeking 10 participants with leukemia, ranging in age from 0 to 120 years old. Qualifying patients must have already entered remission and possess poor prognostic indicators such as AML -5, -7, t(6;9), tri8 or -11 (prep regimens 3 or 4)."
Are senior citizens permitted to join this trial?
"The requirements for this clinical trial state that applicants must be between 0 and 120 years old. According to the registry, there are 1340 medical trials open to minors and 4201 available for adults aged 65 or above."
Share this study with friends
Copy Link
Messenger